Dr. Merry Chen, MD

Dr. Chen practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Chen's NPI, 1003022013, was assigned on May 15, 2007. Dr. Chen graduated from SUNY Downstate Health Sciences University in 2005. Dr. Chen's Texas license number on file is P1061.

Dr. Chen's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Chen's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chen practices. Vendor and product names are available with a free account.

Neurology is Dr. Chen's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Chen is board certified in epilepsy by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Chen's licenses on file in 12 states: Texas, Florida, Massachusetts, Arizona, Georgia, New York, Oklahoma, Alabama, Louisiana, Mississippi, Tennessee and Washington.

Dmand AI lists acute mini-stroke (TIA), carpal tunnel syndrome, cerebrovascular disease, encephalopathy, epilepsy, essential tremor, fibromyalgia and chronic pain and hereditary polyneuropathy among the conditions Dr. Chen treats.

CMS data shows 744 Medicare services from Dr. Chen across 10 procedure codes in 2024, for 552 Medicare patients. Medicare paid $59,264 for them.

CMS counts 552 Medicare patients who saw Dr. Chen in 2024. The largest group is 65 to 74, with 288 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 3.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chen's median patient age at 69, with 61% women.

In 2024, Dr. Chen wrote 393 Medicare Part D claims for 115 patients. 96% of them were for generic drugs. CMS names the drug for 284 of them, across 10 drugs with 11 or more claims each, at $13,023 in total drug cost. In 2023, CMS named 240 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Chen for performance year 2024, reported as part of a group. Dr. Chen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chen as offering telehealth.

Dmand AI links 20 papers to Dr. Chen, published from 2010 to 2024. 2024 was the busiest year, with 3. The most frequent topics are Melanoma and Vesicular Monoamine Transport Proteins. Dr. Chen has published most often in Toxicol Sci. Dr. Chen's most frequent co-authors are Jennifer Leigh McQuade, MD, Rodabe N. Amaria, MD and Paul William Gidley, MD.

Dmand AI links Dr. Chen to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Low Back Pain.

CMS Open Payments shows 10 general payments to Dr. Chen from 7 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 100% of the total. Neurocrine BioSciences, Inc. paid the most, $155.

Dr. Chen graduated from SUNY Downstate Health Sciences University in 2005. Dr. Chen is a member of AAN.

Dr. Chen is in network with 3 carriers, including Aetna, Blue Cross Blue Shield of Michigan and CMS Medicare. HMO plans come from the most carriers, 2. Check the plan with the practice before a visit.